Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America

Detalhes bibliográficos
Autor(a) principal: ROJAS,Juan Ignacio
Data de Publicação: 2021
Outros Autores: PATRUCCO,Liliana, FRUNS,Manuel, HORNUNG,Giesela, FLORES,José, CARNERO CONTENTTI,Edgar, LOPEZ,Pablo Adrian, PETTINICCHI,Juan Pablo, CARIDE,Alejandro, GALLEGUILLOS,Lorna, BARAHONA,Jorge, DIAZ,Violeta, HERNÁNDEZ,Marianella, ALONSO,Ricardo, CRISTIANO,Edgardo
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Arquivos de neuro-psiquiatria (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2021000400305
Resumo: ABSTRACT Background: Despite the abundance of information concerning ocrelizumab in phase III clinical trials, there is scarce evidence regarding real-world patient profiles. Objective: The aim of this study was to investigate patient profiles, effectiveness and persistence with treatment among patients who used ocrelizumab for treatment of multiple sclerosis in Latin America. Methods: This was a retrospective multicenter study in Argentina, Chile and Mexico. Medical record databases on patients who received ocrelizumab were analyzed. Demographic and clinical variables were described, along with effectiveness outcomes, which included the proportions of patients free from clinical relapses, from disability progression and from new or enlarging T2 or T1 gadolinium-enhancing lesions, on annual magnetic resonance imaging. Results: A total of 81 patients were included. The most frequent phenotype was relapsing-remitting MS, in 64.2% of the patients. The mean age at study entry was 41.3 ± 12.0 years and 51.8% were women. A total of 38% had had relapse activity during the 12 months before starting on ocrelizumab, with a mean relapse rate of 1.3 ± 0.6 during that period. 75% were free from clinical relapses and 91% were free from gadolinium-enhancing lesions in the relapsing-remitting course. Ocrelizumab discontinuation during the first 12 months was observed in three patients (3.7%). The mean persistence observed during the first-year follow-up was 338 ± 24 days. Conclusions: Our study is in line with previous randomized clinical trials and recent real-world studies describing patient profiles, effectiveness and persistence regarding ocrelizumab treatment in multiple sclerosis patients in Latin America.
id ABNEURO-1_f8f3acb6fb0539e0b5777989ef527d19
oai_identifier_str oai:scielo:S0004-282X2021000400305
network_acronym_str ABNEURO-1
network_name_str Arquivos de neuro-psiquiatria (Online)
repository_id_str
spelling Real-world experience of ocrelizumab in multiple sclerosis patients in Latin AmericaMultiple SclerosisPharmaceutical PreparationsLatin AmericaEffective LifeABSTRACT Background: Despite the abundance of information concerning ocrelizumab in phase III clinical trials, there is scarce evidence regarding real-world patient profiles. Objective: The aim of this study was to investigate patient profiles, effectiveness and persistence with treatment among patients who used ocrelizumab for treatment of multiple sclerosis in Latin America. Methods: This was a retrospective multicenter study in Argentina, Chile and Mexico. Medical record databases on patients who received ocrelizumab were analyzed. Demographic and clinical variables were described, along with effectiveness outcomes, which included the proportions of patients free from clinical relapses, from disability progression and from new or enlarging T2 or T1 gadolinium-enhancing lesions, on annual magnetic resonance imaging. Results: A total of 81 patients were included. The most frequent phenotype was relapsing-remitting MS, in 64.2% of the patients. The mean age at study entry was 41.3 ± 12.0 years and 51.8% were women. A total of 38% had had relapse activity during the 12 months before starting on ocrelizumab, with a mean relapse rate of 1.3 ± 0.6 during that period. 75% were free from clinical relapses and 91% were free from gadolinium-enhancing lesions in the relapsing-remitting course. Ocrelizumab discontinuation during the first 12 months was observed in three patients (3.7%). The mean persistence observed during the first-year follow-up was 338 ± 24 days. Conclusions: Our study is in line with previous randomized clinical trials and recent real-world studies describing patient profiles, effectiveness and persistence regarding ocrelizumab treatment in multiple sclerosis patients in Latin America.Academia Brasileira de Neurologia - ABNEURO2021-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2021000400305Arquivos de Neuro-Psiquiatria v.79 n.4 2021reponame:Arquivos de neuro-psiquiatria (Online)instname:Academia Brasileira de Neurologiainstacron:ABNEURO10.1590/0004-282x-anp-2020-0339info:eu-repo/semantics/openAccessROJAS,Juan IgnacioPATRUCCO,LilianaFRUNS,ManuelHORNUNG,GieselaFLORES,JoséCARNERO CONTENTTI,EdgarLOPEZ,Pablo AdrianPETTINICCHI,Juan PabloCARIDE,AlejandroGALLEGUILLOS,LornaBARAHONA,JorgeDIAZ,VioletaHERNÁNDEZ,MarianellaALONSO,RicardoCRISTIANO,Edgardoeng2021-06-07T00:00:00Zoai:scielo:S0004-282X2021000400305Revistahttp://www.scielo.br/anphttps://old.scielo.br/oai/scielo-oai.php||revista.arquivos@abneuro.org1678-42270004-282Xopendoar:2021-06-07T00:00Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologiafalse
dc.title.none.fl_str_mv Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America
title Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America
spellingShingle Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America
ROJAS,Juan Ignacio
Multiple Sclerosis
Pharmaceutical Preparations
Latin America
Effective Life
title_short Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America
title_full Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America
title_fullStr Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America
title_full_unstemmed Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America
title_sort Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America
author ROJAS,Juan Ignacio
author_facet ROJAS,Juan Ignacio
PATRUCCO,Liliana
FRUNS,Manuel
HORNUNG,Giesela
FLORES,José
CARNERO CONTENTTI,Edgar
LOPEZ,Pablo Adrian
PETTINICCHI,Juan Pablo
CARIDE,Alejandro
GALLEGUILLOS,Lorna
BARAHONA,Jorge
DIAZ,Violeta
HERNÁNDEZ,Marianella
ALONSO,Ricardo
CRISTIANO,Edgardo
author_role author
author2 PATRUCCO,Liliana
FRUNS,Manuel
HORNUNG,Giesela
FLORES,José
CARNERO CONTENTTI,Edgar
LOPEZ,Pablo Adrian
PETTINICCHI,Juan Pablo
CARIDE,Alejandro
GALLEGUILLOS,Lorna
BARAHONA,Jorge
DIAZ,Violeta
HERNÁNDEZ,Marianella
ALONSO,Ricardo
CRISTIANO,Edgardo
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv ROJAS,Juan Ignacio
PATRUCCO,Liliana
FRUNS,Manuel
HORNUNG,Giesela
FLORES,José
CARNERO CONTENTTI,Edgar
LOPEZ,Pablo Adrian
PETTINICCHI,Juan Pablo
CARIDE,Alejandro
GALLEGUILLOS,Lorna
BARAHONA,Jorge
DIAZ,Violeta
HERNÁNDEZ,Marianella
ALONSO,Ricardo
CRISTIANO,Edgardo
dc.subject.por.fl_str_mv Multiple Sclerosis
Pharmaceutical Preparations
Latin America
Effective Life
topic Multiple Sclerosis
Pharmaceutical Preparations
Latin America
Effective Life
description ABSTRACT Background: Despite the abundance of information concerning ocrelizumab in phase III clinical trials, there is scarce evidence regarding real-world patient profiles. Objective: The aim of this study was to investigate patient profiles, effectiveness and persistence with treatment among patients who used ocrelizumab for treatment of multiple sclerosis in Latin America. Methods: This was a retrospective multicenter study in Argentina, Chile and Mexico. Medical record databases on patients who received ocrelizumab were analyzed. Demographic and clinical variables were described, along with effectiveness outcomes, which included the proportions of patients free from clinical relapses, from disability progression and from new or enlarging T2 or T1 gadolinium-enhancing lesions, on annual magnetic resonance imaging. Results: A total of 81 patients were included. The most frequent phenotype was relapsing-remitting MS, in 64.2% of the patients. The mean age at study entry was 41.3 ± 12.0 years and 51.8% were women. A total of 38% had had relapse activity during the 12 months before starting on ocrelizumab, with a mean relapse rate of 1.3 ± 0.6 during that period. 75% were free from clinical relapses and 91% were free from gadolinium-enhancing lesions in the relapsing-remitting course. Ocrelizumab discontinuation during the first 12 months was observed in three patients (3.7%). The mean persistence observed during the first-year follow-up was 338 ± 24 days. Conclusions: Our study is in line with previous randomized clinical trials and recent real-world studies describing patient profiles, effectiveness and persistence regarding ocrelizumab treatment in multiple sclerosis patients in Latin America.
publishDate 2021
dc.date.none.fl_str_mv 2021-04-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2021000400305
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2021000400305
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/0004-282x-anp-2020-0339
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
dc.source.none.fl_str_mv Arquivos de Neuro-Psiquiatria v.79 n.4 2021
reponame:Arquivos de neuro-psiquiatria (Online)
instname:Academia Brasileira de Neurologia
instacron:ABNEURO
instname_str Academia Brasileira de Neurologia
instacron_str ABNEURO
institution ABNEURO
reponame_str Arquivos de neuro-psiquiatria (Online)
collection Arquivos de neuro-psiquiatria (Online)
repository.name.fl_str_mv Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologia
repository.mail.fl_str_mv ||revista.arquivos@abneuro.org
_version_ 1754212788415234048